{"id":15733,"date":"2020-01-28T17:00:15","date_gmt":"2020-01-28T22:00:15","guid":{"rendered":"https:\/\/www.jeffclarktrader.com\/?p=15733"},"modified":"2020-01-28T17:00:15","modified_gmt":"2020-01-28T22:00:15","slug":"a-cure-for-cancer-could-happen-in-our-lifetime","status":"publish","type":"post","link":"https:\/\/jeffclarktrader.com\/market-minute\/a-cure-for-cancer-could-happen-in-our-lifetime\/","title":{"rendered":"A Cure for Cancer Could Happen in Our Lifetime"},"content":{"rendered":"

Mike’s note<\/strong>: Our goal in the Market Minute <\/em>is to bring you the kind of profitable trading advice that you just won’t find in mainstream media… And, more importantly, that you can use to make massive profits on short-term trades.<\/p>\n

That’s why, when our colleague Jeff Brown recently booked a 430% return for his readers in two months, on one tech stock trade, <\/strong>it got our attention.<\/p>\n

Here’s the thing, though… Jeff Brown’s approach to trading is wholly unique. He scours the world of technology to find the trends that send small-cap companies roaring higher… then positions his readers in stocks with powerful catalysts on the horizon.<\/p>\n

And one such trend, which Jeff reveals below, could be the ticket to even bigger, faster gains in the months ahead<\/a>…<\/p>\n

\n

1.7 million…<\/p>\n

That\u2019s the official estimate of new cancer diagnoses in the U.S. last year. And that’s just in the United States.<\/p>\n

Globally, there were 17 million new cases of cancer in 2018. When official figures for 2019 are tallied, they’ll likely be higher.<\/p>\n

The cost to patients for treating this disease is staggering. Individual treatments can run over $100,000. Projections estimate that in 2020, total cancer treatment costs in the U.S. will reach $173 billion.<\/p>\n

And the human toll is heartbreaking. According to the CDC, cancer is the second most common cause of death in America.<\/p>\n

I don’t write this lightly. I understand what a terrible human toll this disease has taken. I’m sure everybody reading this has been impacted in some way.<\/p>\n

But I believe there’s reason to be optimistic. As a technologist, I believe technology has the power to solve humanity’s greatest challenges. And I believe finding a cure for cancer will be a challenge that technology overcomes.<\/p>\n

Today, I want to show you a technology that’s contributing in a surprising way…<\/p>\n

Software Editing for Your Genome<\/strong><\/h2>\n

The technology I’m referring to is CRISPR-Cas9.<\/p>\n

It stands for Clustered Regularly Interspaced Short Palindromic Repeats\/CRISPR Associated Protein 9.<\/p>\n

It’s a mouthful. I usually just call it “CRISPR.”<\/p>\n

My longtime Bleeding Edge <\/em>readers likely already know, but think of CRISPR as a software development platform for “hacking” plant, animal, and human genomes (your genetic material).<\/p>\n

It is a way to program the genome and remove the “bugs” – or, in genetic terms, the “mutations” – from DNA. Genetic editing can be used to “fix” or improve the genetics of any living thing.<\/p>\n

There are more than 6,000 diseases caused by genetic mutations. Worse, 95% of them have no approved therapy or treatment.<\/p>\n

As incredible as it sounds, CRISPR has the potential to cure all of them.<\/p>\n

To say that this technology is revolutionary is an understatement. And early indication is that CRISPR works.<\/p>\n

Late last year, I attended the 2019 STAT Summit. 2019 was the inaugural summit, and it has immediately become one of the premier conferences in the world of medicine and bioscience.<\/p>\n

One of the most incredible presentations at the STAT 2019 Summit came from Vertex Pharmaceuticals (VRTX) CEO Jeffrey Leiden.<\/p>\n

Vertex has been working with CRISPR Therapeutics (CRSP) on a therapy for sickle cell disease and beta thalassemia. Bad mutations in the hemoglobin gene cause these blood disorders. The therapy is CTX001.<\/p>\n

And Leiden stated directly, “We have essentially cured these diseases. We have cracked the biology of sickle cell and beta [thalassemia].”<\/p>\n

Of course, it’s not FDA-approved yet. The next step for Vertex is to expand the clinical trials to another 45 patients. I’m expecting identical results compared to the first two patients.<\/p>\n

But going off Leiden’s comments, it appears CRISPR technology has cured these diseases caused by genetic mutations.<\/p>\n

But CRISPR is doing more than just treating genetic disease. It’s playing a surprising role in the fight to cure cancer.<\/p>\n

Cancer Cure-All?<\/strong><\/h2>\n

Huge news came out in the fight against cancer last week.<\/p>\n

Researchers from Cardiff University discovered an unusual T cell capable of killing a wide range of cancers. They published the details in Nature Immunology<\/em>, a peer-reviewed scientific journal.<\/p>\n

T cells are a type of white blood cell that seeks out and kills abnormal cells in the body, like cancer cells. We’ve known about them for a long time now. And we already have specific cancer treatments that leverage T cells for treatment, like CAR T therapies.<\/p>\n

But these treatments only work against a small number of cancers. They just aren’t effective against most cancer types.<\/p>\n

That’s why this discovery is so incredible. In testing, researchers at Cardiff found that this specific type of T cell could find and kill cells linked to lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney, and cervical cancers… all while leaving healthy cells intact.<\/p>\n

The ramifications here are extraordinary. What if we had a single treatment that could be used to cure cancer once and for all? That’s potentially what we’re talking about here.<\/p>\n

And here’s an interesting twist that caught my eye – how did the researchers find these unusual T cells?<\/p>\n

Well, they used CRISPR-Cas9 genetic editing technology…<\/p>\n

We just keep finding more and more new applications for this amazing technology. In this case, it was used for the discovery of a certain kind of T cell.<\/p>\n

So, what are the investment implications for CRISPR?<\/p>\n

Sky Is the Limit<\/strong><\/h2>\n

Right now, I suspect that CRISPR technology is unknown by 99% of investors. But as this technology improves, and as we develop more and more treatment for disease with this technology, that will change fast.<\/p>\n

I estimate the total market opportunity for therapies derived from CRISPR\/Cas9 genetic editing to exceed $1 trillion. Essentially, the sky is the limit.<\/p>\n

One of my favorite companies working with this technology is Vertex Pharmaceuticals (VRTX). It’s the company I mentioned above. Already, my readers are up 50% with this stock. And I expect it to go higher in the long run.<\/p>\n

I hope you’re ready. Medicine as we know it is on the verge of changing for good. And it’s not years away.<\/p>\n

It’s happening right now.<\/p>\n

Regards,<\/p>\n

Jeff Brown
Chief Technology Analyst, Bonner & Partners<\/p>\n

P.S.<\/strong> We’re on the cusp of curing diseases that were once thought untreatable. 99% of investors don’t realize this. But they will soon. I believe fortunes will be made in weeks or even days with the right biotech stocks.<\/p>\n

I say this because I’ve spent five years studying a select group of these stocks. And what I noticed is that a small percentage can soar hundreds of percent in days or even hours. And I’ve developed this system to pinpoint them<\/a>.<\/p>\n

If you’d like to see the evidence for yourself, go right here<\/a>.<\/p>\n

But please don’t delay. This presentation will come offline at midnight tonight. Click here and I’ll see you there<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Projections estimate that in 2020, total cancer treatment costs in the U.S. will reach $173 billion…<\/p>\n","protected":false},"author":40,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"service":"","footnotes":""},"categories":[1],"tags":[],"publication":[10],"person":[22],"newsletter-type":[],"ticker":[],"class_list":["post-15733","post","type-post","status-publish","format-standard","hentry","category-market-minute","publication-market-minute","person-jeff-brown"],"acf":[],"_links":{"self":[{"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/posts\/15733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/users\/40"}],"replies":[{"embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/comments?post=15733"}],"version-history":[{"count":0,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/posts\/15733\/revisions"}],"wp:attachment":[{"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/media?parent=15733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/categories?post=15733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/tags?post=15733"},{"taxonomy":"publication","embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/publication?post=15733"},{"taxonomy":"person","embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/person?post=15733"},{"taxonomy":"newsletter-type","embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/newsletter-type?post=15733"},{"taxonomy":"ticker","embeddable":true,"href":"https:\/\/jeffclarktrader.com\/market-minute\/wp-json\/wp\/v2\/ticker?post=15733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}